Erdinc Dursun, Ph.D.
Primary tabs
JAD profile
Associate Editor
Term Expiration:
12/31/2024
Affiliation(s):
Istanbul University - Cerrahpasa; Institute of Neurological Scinences; Department of Neuroscience
ORCID URL:
Areas of Interest:
Alzheimer's and dementia, Alzheimer's disease, Parkinson's disease, Abeta oligomers, cell and molecular biology of neurodegenerative diseases, vitamin D
Biography & Research:
Born in 1977. Got a B.Sc. degree in 2000 from Istanbul University, Faculty of Science, Biology. Got M.Sc. and Ph.D. degrees in 2003 and 2009, respectively from Istanbul University, Cerrahpasa Faculty of Medicine, Department of Medical Biology. Got the title of Assoc. Prof. in 2014. Worked at Rutgers, University of Medicine and Dentistry of New Jersey (UMDNJ) Department of Biochemistry and Molecular Biology / Department of Neuroscience, NJ., USA in 2007 and 2011 as a volunteer researcher. He was PI of two, Co-PI of eight TUBITAK Grants that were focused on molecular mechanisms of vitamin D, neurodegeneration, Alzheimer’s disease, and Parkinson’s disease. He was a Co-PI of Turkey Stakeholder in Biomarkers of Alzheimer’s Disease and Parkinson’s Disease (Joint Project on Neurodegenerative Disease (JPND / BIOMARK-ADPD)-FP7, PI: B.Winblad) and was a Co-PI of Turkey Stakeholder in ADDIA Program EC Horizon 2020 -A multicentre proof of performance clinical study to validate blood-based biomarker candidates for the diagnosis of Alzheimer’s disease (Project no: H2020-SMEINST-2-2014 under the Grant Agreement#674474). Is the Co-Director of Brain and Neurodegenerative Disorders Research Unit, Department of Neuroscience, Institute of Neurological Sciences, Istanbul University-Cerrahpasa, which is the only reference laboratory performing CSF Aβ1-42, total tau and Ptau(181) tests in Turkey, since 2009. The focus of research involves vitamin D action molecular and genetic mechanisms of Alzheimer’s disease and neurodegeneration, molecular aspects of amyloid pathogenesis, biomarkers of Alzheimer’s disease. The laboratory techniques include disease modeling via amyloid-beta applications, siRNA treatments, a-synuclein overexpression on neuronal cell lines, primary neuron cultures including hippocampal, cortical cultures, brain organotypic slice cultures, microscopic analysis, mRNA and protein expression analysis, genetic analysis on DNAs, biomarker analysis on CSF and serum samples of AD and PD patients.
